| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/08/2009 | EP1448566B3 Chemokine receptor antagonists and methods of use thereof |
| 04/08/2009 | EP1442026B1 Triazole derivatives as cyclooxygenase (cox) inhibitors |
| 04/08/2009 | EP1212299B1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 04/08/2009 | EP1096953B1 Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses |
| 04/08/2009 | EP1007569B1 Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope |
| 04/08/2009 | EP0931063B3 N-substituted indol-3-glyoxylamid with antiasthmatic, antiallergic and immunosuppressive/immunomodulating effect |
| 04/08/2009 | EP0861266B3 Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them |
| 04/08/2009 | CN101405260A Amine derivatives |
| 04/08/2009 | CN101404985A Autoimmune conditions and NADPH oxidase defects |
| 04/08/2009 | CN101402982A Mud snail glue polysaccharide, preparation method and application thereof |
| 04/08/2009 | CN101401939A Anti-activated state T cell antibody vaccine for preventing and/or treating immune correlated disease |
| 04/08/2009 | CN101401934A T cell component vaccine for preventing and/or treating immune correlated diseases |
| 04/08/2009 | CN101401921A Microbial ecological traditional Chinese medicine preparation for livestock and poultry from fermentation production of multiple bacterials and fermentation method thereof |
| 04/08/2009 | CN101401907A Particle for increasing body resistance and consolidating constitution |
| 04/08/2009 | CN101401904A Panax ginseng and campanumaea pilosula composition and preparation thereof |
| 04/08/2009 | CN101401898A Chinese medicinal composition for improving phylactic power |
| 04/08/2009 | CN101401860A Externally-applied medicament composition for treating dermatosis |
| 04/08/2009 | CN101401820A Injection novel medicine for treating systematic lupus erythematosus |
| 04/08/2009 | CN101401813A Panaxatriol saponin composition and uses in preparing medicament for immunity enhancement |
| 04/08/2009 | CN101401805A Vitamin E supplementation to tetanus toxoid |
| 04/08/2009 | CN101401789A Cordyceps sinensis polysaccharide liposome medicament and preparation thereof |
| 04/08/2009 | CN100475953C Pancreatic stem cells |
| 04/08/2009 | CN100475843C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 04/08/2009 | CN100475254C Anti-fatigue resistibility capsules for improving body immunity and method for making same |
| 04/08/2009 | CN100475240C Animal immunopotentiator using white atractylodes rhizome as main material |
| 04/08/2009 | CN100475203C Preparing method of triptolide molecule microcapsule |
| 04/08/2009 | CN100475190C Implantation slow release medicine in eyes |
| 04/07/2009 | US7514571 Bicyclo derivative |
| 04/07/2009 | US7514564 Substituted amine derivatives and methods of use |
| 04/07/2009 | US7514541 crosslinking with curing agents in acidic or alkaline conditions, to form to products used in cosmetic, medical and pharmaceutical applications |
| 04/07/2009 | US7514535 Chimeric immunogens |
| 04/07/2009 | US7514469 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse |
| 04/07/2009 | US7514456 Nicotinamide derivatives useful as p38 inhibitors |
| 04/07/2009 | US7514454 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders |
| 04/07/2009 | US7514449 inhibitor of activated blood coagulation factor X; N-(5-chloropyridin-2-yl)-3- {[(trans-4-pyrrolidin-1 -ylcyclohexyl)carbonyl]aznino}furo[3,2-c]pyridine-2-carboxaxnide; disorders caused by thrombi and emboli in a mammal; decreased toxicity, and causes few side effects |
| 04/07/2009 | US7514429 Benzoxazinone-derived compounds, their preparation and use as medicaments |
| 04/07/2009 | US7514405 Method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable |
| 04/07/2009 | US7514398 Growth factor complex |
| 04/07/2009 | US7514239 Nucleotide sequences coding polypeptide for use in the treatment of preferential glandular disorders |
| 04/07/2009 | US7514225 detecting drugs that inhibits the binding of macrophage migration inhibitory factor (MIF) to an antimacrophage migration inhibitor factor monoclonal or polyclonal antibody; drug screening |
| 04/07/2009 | US7514105 Bioavailability/bioefficacy enhancing activity of Cuminum cyminum and extracts and fractions thereof |
| 04/07/2009 | US7514095 Three-dimensional chitosan matrix or drug release; tissue engineering ; water in oil emulsion containing active materials; extrusion; coagulation |
| 04/07/2009 | US7514087 Administering primer and boosting composition comprising source of one or more CD8+ T cell epitopes of melanoma from a source of non-replicating or replication-deficient recombinant poxvirus vector in the human |
| 04/07/2009 | US7514073 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders |
| 04/07/2009 | CA2493633C Kinase inhibitors |
| 04/07/2009 | CA2463294C Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/07/2009 | CA2458684C Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
| 04/07/2009 | CA2415890C N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 04/07/2009 | CA2413190C Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 04/07/2009 | CA2372384C Anti-inflammatory bioactive glass particulates |
| 04/07/2009 | CA2361998C Aromatic heterocyclic compounds as anti-inflammatory agents |
| 04/07/2009 | CA2352503C Il-5 inhibiting 6-azauracil derivatives |
| 04/07/2009 | CA2339253C Inhibitors of p38 |
| 04/07/2009 | CA2313704C Recombinant nodavirus compositions and methods |
| 04/07/2009 | CA2237157C Cyclopeptolide inhibitors of adhesion molecules |
| 04/07/2009 | CA2204652C Composition for prevention and treatment of hiv-1 infection comprising at least two different hiv-1 reverse transcriptase inhibitors |
| 04/07/2009 | CA2175332C Haemophilus transferrin receptor genes |
| 04/07/2009 | CA2118239C 1h-imidazo{4,5-c}quinolin-4-amines as vaccine adjuvants |
| 04/07/2009 | CA2117492C Bystander suppression of autoimmune diseases |
| 04/02/2009 | WO2009042806A1 Polo-like kinase inhibitors |
| 04/02/2009 | WO2009042711A1 Polo-like kinase inhibitors |
| 04/02/2009 | WO2009041714A1 External preparation for free radical diseases |
| 04/02/2009 | WO2009041613A1 Modified antibody constant region |
| 04/02/2009 | WO2009041591A1 Fused pyridine derivative |
| 04/02/2009 | WO2009041570A1 Polymer conjugate of steroid |
| 04/02/2009 | WO2009041456A1 Imidazopyridazine derivative |
| 04/02/2009 | WO2009041026A1 Cxcl10 production inhibitor |
| 04/02/2009 | WO2009040849A1 Use of amino acid l-kynurenine and derivatives thereof for the treatment of chronic inflammatory pathologies |
| 04/02/2009 | WO2009040310A1 Prevention of allergy at weaning |
| 04/02/2009 | WO2009040089A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 04/02/2009 | WO2009040088A1 Use of peptide kvlpvpq as a therapeutic agent |
| 04/02/2009 | WO2009040086A2 Use of salusin-alpha as a therapeutic agent |
| 04/02/2009 | WO2009040085A2 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 04/02/2009 | WO2009040084A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040083A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040073A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040072A2 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040071A2 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040070A2 Use of helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040068A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040067A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040051A2 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 04/02/2009 | WO2009040050A2 Use of calcitonin as anti-angiogenic agent |
| 04/02/2009 | WO2009040049A2 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents |
| 04/02/2009 | WO2009040046A2 Use of stresscopin-related peptide as a therapeutic agent |
| 04/02/2009 | WO2009040045A2 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
| 04/02/2009 | WO2009040035A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040034A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040033A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040032A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040031A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040030A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040029A2 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040028A2 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040027A1 Use of the peptide stresscopin as a therapeutic agent |
| 04/02/2009 | WO2009040025A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 04/02/2009 | WO2009040024A2 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections |
| 04/02/2009 | WO2009040023A2 Use of galnon as a therapeutic agent |
| 04/02/2009 | WO2009040022A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040021A2 Use of a peptide as a therapeutic agent |